• Protocols

• EAY191N4

  OPEN TO ACCRUAL

  Ph2 Randomized Selumetinib, Olaparib or Selumetinib in Patients w/Ovarian and Endometrial Cancer
  
  

• GOG3098

  OPEN TO ACCRUAL

  DESTINY-Endometrial01: Ph III T-DXd + Rilvegostomig or Pembro vs Chemo + Pembro for Endometrial